Oppenheimer analyst Hartaj Singh downgraded aTyr Pharma to Perform from Outperform without a price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LIFE:
- aTyr Pharma announcse EC granted ODD for efzofitimod
- aTyr Pharma to present on efzofitimod at WASOG conference
- aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference
- aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference
Questions or Comments about the article? Write to editor@tipranks.com